BioGend Therapeutics Co., Ltd.
TWO: 6733.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Te-Li Chen
- Employees
- 34
- Headquarters
- Taipei, Taiwan
- IPO year
- 2019
- Market cap
- NT$3.5B
- Website
- https://www.biogend.com
Loading 6733…
Loading profile data…Frequently asked questions about 6733
What does BioGend Therapeutics Co., Ltd. (6733.TWO) do?
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
Where does 6733.TWO trade?
BioGend Therapeutics Co., Ltd. (6733.TWO) trades on the Taipei Exchange.
What sector is 6733.TWO in?
BioGend Therapeutics Co., Ltd. (6733.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioGend Therapeutics Co., Ltd.?
Te-Li Chen is the chief executive officer of BioGend Therapeutics Co., Ltd. (6733.TWO).
Where is BioGend Therapeutics Co., Ltd. headquartered?
BioGend Therapeutics Co., Ltd. is headquartered in Taiwan.
Does 6733.TWO pay a dividend?
BioGend Therapeutics Co., Ltd. (6733.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6733.TWO go public?
BioGend Therapeutics Co., Ltd. (6733.TWO) completed its initial public offering in 2019.